Literature DB >> 3982902

Auditory nerve and brainstem responses in newborn infants with hyperbilirubinemia.

H Nakamura, S Takada, R Shimabuku, M Matsuo, T Matsuo, H Negishi.   

Abstract

To assess early bilirubin toxicity, a study was made of auditory brainstem responses in relation to total bilirubin levels as well as unbound bilirubin levels in 56 hyperbilirubinemic infants (total bilirubin greater than or equal to 15.0 mg/dL) and 24 infants who did not have jaundice. The latencies of wave I at 85 dB HL (hearing level) in hyperbilirubinemic infants were significantly greater than those in the control group. The latencies of wave I and V in hyperbilirubinemic infants with unbound bilirubin levels greater than or equal to 1.0 microgram/dL (group C) were greater than those in the control group and in the hyperbilirubinemic infants with unbound bilirubin levels less than 0.5 microgram/dL (group A) and with unbound bilirubin levels less than 1.0 microgram/dL (group B). There were no significant differences of the wave I-V interpeak latency between the control infants and the hyperbilirubinemic infants. Thirty of the 80 infants showed prolonged peak latencies (greater than the mean +/- 2 SD for the control infants) of wave I and/or V in one or both ears. The incidences of the prolonged peak latencies in group B (42%) and group C (89%) were significantly greater than that in the control group (12%). The serial determinations of auditory brainstem responses in infants treated with exchange transfusions revealed that the prolonged peak latencies before exchange transfusion improved at 48 and 96 hours after the procedure for wave I, and at 24, 48, and 96 hours after the procedure for wave V. The interpeak latency of wave I-V did not change with exchange transfusion.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3982902

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  28 in total

Review 1.  The blood-brain barrier and bilirubin encephalopathy.

Authors:  R P Wennberg
Journal:  Cell Mol Neurobiol       Date:  2000-02       Impact factor: 5.046

Review 2.  Is neonatal jaundice associated with Autism Spectrum Disorders: a systematic review.

Authors:  Sanjiv B Amin; Tristram Smith; Hongyue Wang
Journal:  J Autism Dev Disord       Date:  2011-11

Review 3.  Use of evoked potentials in preterm neonates.

Authors:  M J Taylor; E Saliba; J Laugier
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1996-01       Impact factor: 5.747

4.  Intravenous lipid and bilirubin-albumin binding variables in premature infants.

Authors:  Sanjiv B Amin; Theresa Harte; Lori Scholer; Hongyue Wang
Journal:  Pediatrics       Date:  2009-07       Impact factor: 7.124

5.  Frequency-following response among neonates with progressive moderate hyperbilirubinemia.

Authors:  Gabriella Musacchia; Jiong Hu; Vinod K Bhutani; Ronald J Wong; Mei-Ling Tong; Shuping Han; Nikolas H Blevins; Matthew B Fitzgerald
Journal:  J Perinatol       Date:  2019-07-01       Impact factor: 2.521

6.  Comparative evaluation of Transient Evoked Oto-acoustic Emissions and Brainstem Evoked Response Audiometry as screening modality for hearing impairment in neonates.

Authors:  Rajiv Dhawan; N N Mathur
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2007-04-26

7.  Assessing the risk of kernicterus.

Authors:  H Nakamura
Journal:  Indian J Pediatr       Date:  1987 Sep-Oct       Impact factor: 1.967

Review 8.  Newborn jaundice technologies: unbound bilirubin and bilirubin binding capacity in neonates.

Authors:  Sanjiv B Amin; Angelo A Lamola
Journal:  Semin Perinatol       Date:  2011-06       Impact factor: 3.300

9.  Effects of bilirubin on visual evoked potentials in term infants.

Authors:  Y J Chen; W M Kang
Journal:  Eur J Pediatr       Date:  1995-08       Impact factor: 3.183

10.  Unbound Bilirubin and Auditory Neuropathy Spectrum Disorder in Late Preterm and Term Infants with Severe Jaundice.

Authors:  Sanjiv B Amin; Hongyue Wang; Nirupama Laroia; Mark Orlando
Journal:  J Pediatr       Date:  2016-03-04       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.